Literature DB >> 4082917

Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.

F Bermejo Pareja, P Martinez-Martin, V Muradas, J G de Yébenes.   

Abstract

Thirty-four patients with advanced Parkinson's disease showing intolerance to therapeutic doses of L-DOPA were treated with L-DOPA plus carbidopa at two different proportions. Ten patients preferred medication containing 10% carbidopa while 24 preferred 25% carbidopa. The increase of carbidopa reduced gastrointestinal disturbances and psychiatric side effects related to L-DOPA, but improvement of disability when measured according to objective tests was modest. Higher doses of carbidopa reduced peripheral DOPA metabolism and increased blood levels of tryptophan, 3-OM-DOPA and DOPA in relation to the administered dose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082917     DOI: 10.1111/j.1600-0404.1985.tb00908.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats.

Authors:  P S Leppert; M Cortese; J A Fix
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

2.  Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Authors:  E Bredberg; H Lennernäs; L Paalzow
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 4.  Bladder and bowel dysfunction in Parkinson's disease.

Authors:  R Sakakibara; T Uchiyama; T Yamanishi; K Shirai; T Hattori
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

5.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

6.  Bladder, bowel, and sexual dysfunction in Parkinson's disease.

Authors:  Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Fuyuki Tateno; Tomoyuki Uchiyama; Tatsuya Yamamoto; Tomonori Yamanishi
Journal:  Parkinsons Dis       Date:  2011-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.